KalVista Pharmaceuticals, Inc. Stock

$12.25

2.08% yesterday

Nasdaq, Aug 12, 10:08 pm CET

ISIN

US4834971032

Symbol

KALV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

KalVista Pharmaceuticals, Inc. Stock price

$12.25

-0.50 3.92% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

-0.26 2.08%

ISIN

US4834971032

Symbol

KALV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$624.9m

Enterprise Value

$510.2m

Net debt

positive

Cash

$220.6m

Shares outstanding

49.8m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | 15.5

EV/Sales

- | 12.7

EV/FCF

negative

P/B

6.6

Financial Health

Equity Ratio

38.0%

Return on Equity

ROCE

ROIC

Debt/Equity

1.1

Financials (TTM | estimate)

Revenue

- | $40.3m

EBITDA

- | $-168.2m

EBIT

- | $-182.4m

Net Income

- | $-145.3m

Free Cash Flow

$-153.8m

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

KalVista Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from KalVista Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Oct '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	81 81	130% 130% -
- Research and Development Expense	91 91	10% 10% -
EBITDA	-171 -171	46% 46% -
- Depreciation and Amortization	0.88 0.88	13% 13% -
EBIT (Operating Income) EBIT	-172 -172	46% 46% -
Net Profit	-156 -156	55% 55% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

KalVista Pharmaceuticals, Inc. Stock News

Neutral

GlobeNewsWire

●

one day ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors.

Neutral

Business Wire

●

one day ago

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) confirmed maintenance of orphan designation for sebetralstat, underscoring the critical unmet need that sebetralstat addresses in the European Union (EU). Sebetralstat, a novel, oral p...

Neutral

Business Wire

●

9 days ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted six newly-hired employees inducement options to purchase an aggregate of 44,000 shares of KalVista common stock on August 1, 2025 as inducements material to each employee entering into employment with KalV...

More KalVista Pharmaceuticals, Inc. News

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.

Head office	United States
CEO	Ben Palleiko
Employees	150
Founded	2004
Website	www.kalvista.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now